Exposure and Response Prevention for OCD

Overseen By Amy Rapp, Ph.D.

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: Icahn School of Medicine at Mount Sinai

Must not be taking: Psychiatric medications

Disqualifiers: Psychiatric disorders, OCD family history, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 17

Duration: 10 weeks

100 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Psychiatric disorders characterized by compulsivity, such as obsessive-compulsive disorder (OCD), result in considerable functional impairment and many individuals do not respond to gold-standard treatments. Compulsivity has long been thought to occur due to exaggerated habits and reduced goal-directed control, although more recently, this conceptualization of compulsivity as an imbalance of two cognitive systems has been challenged as overly narrow. This study will recruit 100 individuals (50 adults diagnosed with OCD, 50 healthy controls) and leverage the measurement precision offered by theory-driven computational modeling in combination with electroencephalogram (EEG) to go beyond this binary theory of compulsivity, revealing how more complex interactions of neurocognitive subcomponents contribute to compulsivity-information that could ultimately lead to improved treatment personalization and clinical outcomes.

Who Is on the Research Team?

Amy Rapp, PhD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Are You a Good Fit for This Trial?

This trial is for adults diagnosed with Obsessive-Compulsive Disorder (OCD) and healthy individuals without OCD. The study aims to include 50 participants from each group, totaling 100. Specific eligibility criteria are not provided in the given information.

Inclusion Criteria

Participants must be English-speaking

Participants must be able to provide consent

I am between 18 and 55 years old.

Exclusion Criteria

I have OCD but no other major psychiatric disorders.

I do not have a parent or sibling diagnosed with OCD.

Individuals diagnosed with OCD will be excluded if it is unsafe for them to participate in research

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants diagnosed with OCD receive 17 sessions of exposure and response prevention therapy over 10 weeks

10 weeks

17 sessions (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Exposure and Response Prevention

Trial Overview The study is testing a new approach to understanding compulsivity in OCD by using computational modeling and EEG. It seeks to move beyond traditional theories by examining complex neurocognitive interactions, which could help personalize treatments.

How Is the Trial Designed?

Group I: Participants diagnosed with OCD Experimental Treatment 1 Intervention

All participants diagnosed with Obsessive Compulsive Disorder (OCD) who enroll in this study will receive 17 sessions of exposure and response prevention, a specialized cognitive behavioral therapy for OCD, over the course of 10 weeks.

Group II: Healthy controls Active Control 1 Intervention

Individuals who do not have a current or lifetime psychiatric diagnosis will not receive any treatment.

Who Is Running the Clinical Trial?

Icahn School of Medicine at Mount Sinai

Lead Sponsor

Trials

933

Recruited

579,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials

3,007

Recruited

2,852,000+